Literature DB >> 33406472

A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients.

Andisiwe Malo1, Tracy Kellermann2, Elisa H Ignatius3, Kelly E Dooley3, Rodney Dawson4, Anton Joubert5, Jennifer Norman5, Sandra Castel5, Lubbe Wiesner5.   

Abstract

A method for the extraction and quantification of pretomanid in 40 μL of human plasma, by high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) detection was developed and validated. Samples were prepared using liquid-liquid extraction and chromatographic separation was achieved on an Agilent Poroshell C18 column using an isocratic elution at a flow rate of 400 μL/min. Electrospray ionization with mass detection at unit resolution in the multiple reaction monitoring (MRM) mode on an AB Sciex API 3200 mass spectrometer was used. Over the validation period, accuracy, precision, selectivity, sensitivity, recovery and stability were assessed. The calibration range was 10 - 10 000 ng/mL. Inter- and intra-day precision, expressed as the coefficient of variation (%CV), was shown to be lower than 9% at all concentrations tested with accuracies between 95.2 and 110 %. The recovery was 72.4 % overall and reproducible at the low, medium and high end of the calibration range. The method was shown to be specific for pretomanid with no significant matrix effects observed. The validated method facilitated the analysis of pretomanid in plasma collected from adults with pulmonary TB as part of a clinical pharmacokinetic study.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  LC–MS/MS; Liquid-liquid extraction; Pretomanid; Tuberculosis (TB); Validation

Mesh:

Substances:

Year:  2020        PMID: 33406472      PMCID: PMC7868581          DOI: 10.1016/j.jpba.2020.113885

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  15 in total

1.  Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.

Authors:  Andreas H Diacon; Rodney Dawson; Madeleine Hanekom; Kim Narunsky; Stefan J Maritz; Amour Venter; Peter R Donald; Christo van Niekerk; Karl Whitney; Doris J Rouse; Martino W Laurenzi; Ann M Ginsberg; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

2.  Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.

Authors:  David F Bruhn; Michael S Scherman; Aman P Singh; Lei Yang; Jiuyu Liu; Anne J Lenaerts; Richard E Lee
Journal:  Bioorg Med Chem Lett       Date:  2015-12-07       Impact factor: 2.823

3.  Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis.

Authors:  B K Matuszewski
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-11-23       Impact factor: 3.205

4.  Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.

Authors:  Ann M Ginsberg; Martino W Laurenzi; Doris J Rouse; Karl D Whitney; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

5.  Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Authors:  Kelly E Dooley; Anne F Luetkemeyer; Jeong-Gun Park; Reena Allen; Yoninah Cramer; Stephen Murray; Deborah Sutherland; Francesca Aweeka; Susan L Koletar; Florence Marzan; Jing Bao; Rada Savic; David W Haas
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

6.  Phase II dose-ranging trial of the early bactericidal activity of PA-824.

Authors:  Andreas H Diacon; Rodney Dawson; Jeannine du Bois; Kim Narunsky; Amour Venter; Peter R Donald; Christo van Niekerk; Ngozi Erondu; Ann M Ginsberg; Piet Becker; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

7.  Tuberculosis: a neglected disease strikes back.

Authors:  S H Kaufmann; J D van Embden
Journal:  Trends Microbiol       Date:  1993-04       Impact factor: 17.079

Review 8.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study.

Authors:  Libin Wang; Yue Xu; Li Liang; Chunyan Diao; Xueying Liu; Jianchun Zhang; Shengyong Zhang
Journal:  J Pharm Biomed Anal       Date:  2014-04-05       Impact factor: 3.935

10.  Pharmacokinetics and tissue distribution study of PA-824 in rats by LC-MS/MS.

Authors:  Libin Wang; Yetao Ma; Hongtao Duan; Jiahui Yao; Li Liang; Ruitao Zhang; Xuejiao Zhou; Xueying Liu; Qingwei Wang; Shengyong Zhang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-10-29       Impact factor: 3.205

View more
  1 in total

Review 1.  Pretomanid for tuberculosis treatment: an update for clinical purposes.

Authors:  Sara Occhineri; Tommaso Matucci; Laura Rindi; Giusy Tiseo; Marco Falcone; Niccolò Riccardi; Giorgio Besozzi
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.